Improved oral absorption of exenatide using an original nanoencapsulation and microencapsulation approach

Journal of Controlled Release

Volumn 217, Issue , 2015, Pages 202-210

  Soudry Kochavi, Liat ^a   Naraykin, Natalya ^a   Nassar, Taher ^a   Benita, Simon ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Albumin; Bioavailability; Dextran; Exenatide; Microparticle; Nanoparticle; Oral

Indexed keywords

BIOCHEMISTRY; CROSSLINKING; DEXTRAN; DISEASE CONTROL; NANOPARTICLES; PEPTIDES;

ALBUMIN; BIOAVAILABILITY; EXENATIDE; MICRO PARTICLES; ORAL;

PROTEINS;

EUDRAGIT; EXENDIN 4; HYDROXYPROPYLMETHYLCELLULOSE; ANTIDIABETIC AGENT; BOVINE SERUM ALBUMIN; DEXTRAN; DRUG CARRIER; METHYLMETHACRYLATE-METHACRYLIC ACID COPOLYMER; NANOPARTICLE; PEPTIDE; POLYMETHACRYLIC ACID DERIVATIVE; POLYPHOSPHATE; TRIMETAPHOSPHORIC ACID; VENOM;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CROSS LINKING; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG UPTAKE; INTESTINE CELL; MALE; MICROENCAPSULATION; NANOENCAPSULATION; NONHUMAN; PRIORITY JOURNAL; RAT; ZETA POTENTIAL; ANIMAL; BIOAVAILABILITY; BLOOD; CHEMISTRY; DRUG FORMULATION; DRUG RELEASE; INTESTINE ABSORPTION; ORAL DRUG ADMINISTRATION; SPRAGUE DAWLEY RAT;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; DEXTRANS; DRUG CARRIERS; DRUG COMPOUNDING; DRUG LIBERATION; HYPOGLYCEMIC AGENTS; HYPROMELLOSE DERIVATIVES; INTESTINAL ABSORPTION; MALE; NANOPARTICLES; PEPTIDES; POLYMETHACRYLIC ACIDS; POLYPHOSPHATES; RATS, SPRAGUE-DAWLEY; SERUM ALBUMIN, BOVINE; VENOMS;

EID: 84941892373     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2015.09.012     Document Type: Article

References (41)

1. J.L. Cleland, A. Daugherty, and R. Mrsny Emerging protein delivery methods Curr. Opin. Biotechnol. 12 2001 212 219
2. R.J.Y. Ho, and M. Gibaldi Advanced drug delivery R.J.Y. Ho, M. Gibaldi, Biotechnology and Biopharmaceuticals 2003 Wiley-Liss Hoboken, New Jersey 339 380
3. G.P. Carino, and E. Mathiowitz Oral insulin delivery Adv. Drug Deliv. Rev. 35 1999 249 257
4. M. Morishita, and N.A. Peppas Is the oral route possible for peptide and protein drug delivery? Drug Discov. Today 11 2006 905 910
5. L. Jorgensen, E.H. Moeller, M. van de Weert, H.M. Nielsen, and S. Frokjaer Preparing and evaluating delivery systems for proteins Eur. J. Pharm. Sci. 29 2006 174 182
6. K. Tsuji, and K. Tsutani Approval of new biopharmaceuticals 1999-2006: comparison of the US, EU and Japan situations Eur. J. Pharm. Biopharm. 68 2008 496 502
7. G. Orive, R.M. Hernández, A. Rodríguez Gascón, A. Domínguez-Gil, and J.L. Pedraz Drug delivery in biotechnology: present and future Curr. Opin. Biotechnol. 14 2003 659 664
8. J.H. Hamman, G.M. Enslin, and A.F. Kotze Oral delivery of peptide drugs: barriers and developments BioDrugs 19 2005 165 177
9. M.D. Joshi, and R.H. Muller Lipid nanoparticles for parenteral delivery of actives Eur. J. Pharm. Biopharm. 71 2009 161 172
10. J. Kluge, F. Fusaro, G. Muhrer, R. Thakur, and M. Mazzotti Rational design of drug-polymer co-formulations by CO2 anti-solvent precipitation J. Supercrit. Fluids 48 2009 176 182
11. W. Mehnert, and K. Mader Solid lipid nanoparticles: production, characterization and applications Adv. Drug Deliv. Rev. 47 2001 165 196
12. R.N. Gursoy, and S. Benita Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs Biomed. Pharmacother. 58 2004 173 182
13. A.J. Almeida, and E. Souto Solid lipid nanoparticles as a drug delivery system for peptides and proteins Adv. Drug Deliv. Rev. 59 2007 478 490
14. U. Bilati, E. Allémann, and E. Doelker Strategic approaches for overcoming peptide and protein instability within biodegradable nano- and microparticles Eur. J. Pharm. Biopharm. 59 2005 375 388
15. R.C. Mundargi, V.R. Babu, V. Rangaswamy, P. Patel, and T.M. Aminabhavi Nano/microtechnologies for delivering macromolecular therapeutics using poly(d,l-lactide-co-glycolide) and its derivatives J. Control. Release 125 2008 193 209
16. R. Eldor, M. Kidron, Y. Greenberg-Shushlav, and E. Arbit Novel glucagon-like peptide-1 analog delivered orally reduces postprandial glucose excursions in porcine and canine models J. Diabetes Sci. Technol. 4 2010 1516 1523
17. H.N. Nguyen, S.P. Wey, J.H. Juang, K. Sonaje, Y.C. Ho, E.Y. Chuang, C.W. Hsu, T.C. Yen, K.J. Lin, and H.W. Sung The glucose-lowering potential of exendin-4 orally delivered via a pH-sensitive nanoparticle vehicle and effects on subsequent insulin secretion in vivo Biomaterials 32 2011 2673 2682
18. J. Eng, W.A. Kleinman, L. Singh, G. Singh, and J.P. Raufman Isolation and characterization of exendin-4, an exendin-3 analogue, from heloderma suspectum venom J. Biol. Chem. 267 1992 7402 7405
19. M.B. Davidson, G. Bate, and P. Kirkpatrick Exenatide Nat. Rev. Drug Discov. 4 2005 713 714
20. B.R. Gedulin, P.A. Smith, C.M. Jodka, K. Chen, S. Bhavsar, L.L. Nielsen, D.G. Parkes, and A.A. Young Pharmacokinetics and pharmacodynamics of exenatide following alternate routes of administration Int. J. Pharm. 356 2008 231 238
21. M.A. Tracy, K.L. Ward, and L. Firouzabadian Factors affecting the degradation rate of poly(lactide-co-glycolide) microspheres in vivo and in vitro Biomaterials 20 1999 1057 1062
22. D.J. Drucker, J.B. Buse, K. Taylor, D.M. Kendall, M. Trautmann, D. Zhuang, and L. Porter Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. For the DURATION-1 study group Lancet 372 2008 1240 1250
23. H. Linnebjerg, S. Park, P.A. Kothare, M.E. Trautmann, K. Mace, M. Fineman, I. Wilding, M. Nauck, and M. Horowitz Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes Regul. Pept. 151 2008 123 129
24. C. Weber, C. Coester, J. Kreuter, and K. Langer Desolvation process and surface characterization of protein nanoparticles Int. J. Pharm. 194 2000 91 102
25. S. Skrajnar, M. Cerne, M. Bozic, and L. Peternel Effect of replacement fluids saline, gelofusine, and blood on biochemical and hematological parameters in rats subjected to repeated blood sampling Med. Sci. Monit. 15 2009 293 300
26. A. Prokop, C.A. Holland, E. Kozlov, B. Moore, and R.D. Tanner Water-based nanoparticulate polymeric system for protein delivery: permeability control and vaccine application Biotechnol. Bioeng. 75 2 2001 228 232 20
27. S. Mizrahy, and D. Peer Polysaccharides as building blocks for nanotherapeutics Chem. Soc. Rev. 41 2012 2623 2640
28. I.S. Kim, Y.I. Jeong, D.H. Kim, Y.H. Lee, and S.H. Kim Albumin release from biodegradable hydrogels composed of dextran and poly(ethylene glycol) macromer Arch. Pharm. Res. 24 2001 69 73
29. W.N.E. van Dijk-Wolthuis, O. Franssen, H. Talsma, M.J. van Steenbergen, J.J. Kettenes-van den Bosch, and W.E. Hennink Synthesis, characterization and polymerization of glycidyl methacrylate derivatized dextran Macromolecules 28 1995 6317 6322
30. T.W. Sery, and E.J. Hehre Degradation of dextrans by enzymes of intestinal bacteria J. Bacteriol. 71 1956 373 380
31. F. Yuan-yuan, W. Li-jun, L. Dong, L. Bing-zheng, B. Bhesh, C. Xiao Dong, and M. Zhi-huai Preparation of crosslinked starch microspheres and their drug loading and releasing properties Carbohydr. Polym. 74 2008 379 384
32. D. Xu, F. Wu, Y. Chen, K. Wei, and W. Yuan pH-sensitive degradable nanoparticles for highly efficient intracellular delivery of exogenous protein Int. J. Nanomedicine 8 2013 3405 3414
33. Z. Li, and L. Gu Fabrication of self-assembled (-)-epigallocatechin gallate (EGCG) ovalbumin - dextran conjugate nanoparticles and their transport across monolayers of human intestinal epithelial Caco-2 cells J. Agric. Food Chem. 62 2014 1301 1309
34. T. Nassar, A. Rom, A. Nyska, and S. Benita Novel double coated nanocapsules for intestinal delivery and enhanced oral bioavailability of tacrolimus, a P-gp substrate drug J. Control. Release 133 2009 77 84
35. H.-K. Chan, A. Clark, I. Gonda, M. Mumenthaler, and C. Hsu Spray dried powders and powder blends of recombinant human deoxyribonuclease (rhDNase) for aerosol delivery Pharm. Res. 14 1997 431 437
36. B. Zhang, D. He, Y. Fan, N. Liu, and Y. Chen Oral delivery of exenatide microspheres prepared by cross-linking of alginate and hyaluronate PLoS One 9 1 2014 (Published Online 2014 Jan 21)
37. Y. Jin, Y. Song, X. Zhu, D. Zhou, C. Chen, Z. Zhang, and Y. Huang Goblet cell targeting nanoparticles for oral insulin delivery and the influence of mucus on insulin transport Biomaterials 33 2012 1573 1582
38. X. Li, C. Wang, R. Liang, F. Sun, Y. Shi, A. Wang, W. Liu, K. Sun, and Y. Li The glucose-lowering potential of exenatide delivered orally via goblet cell- targeting nanoparticles Pharm. Res. 2014 (Oct 1., Epub ahead of print)
39. S. Attili-Qadria, N. Karra, A. Nemirovskia, O. Schwob, Y. Talmon, T. Nassar, and S. Benita Oral delivery system prolongs blood circulation of docetaxel nanocapsules via lymphatic absorption Proc. Natl. Acad. Sci. U. S. A. 110 43 2013 17498 17503 22
40. Y. Takakura, S. Matsumoto, M. Hashida, and H. Sezaki Enhanced lymphatic delivery of mitomycin C conjugated with dextran Cancer Res. 44 1984 2505 2510
41. S. Pustylnikov, D. Sagar, P. Jain, and Z. Khan Targeting the c-type lectins-mediated host-pathogen interactions with dextran J. Pharm. Pharm Sci. 17 3 2014 371 392